12:00 AM
 | 
Feb 25, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Soluble guanylate cyclase (sGC)

Renal disease

INDICATION: Diabetic nephropathy

Rat studies suggest activating sGC could help treat diabetic nephropathy. In a rat model of diabetic nephropathy, oral 0.3, 1, 3 and 10 mg/kg doses of an undisclosed sGC activator decreased urinary protein excretion, levels of kidney damage markers and the number...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >